Showing posts with label Clinical. Show all posts
Showing posts with label Clinical. Show all posts

Saturday, September 28, 2013

0 Update in clinical allergy and immunology









Keywords:




  • asthma;

  • atopic dermatitis;

  • clinical immunology;

  • eosinophils;

  • innate immunity






Abstract




In the recent years, a tremendous body of studies has addressed a broad variety of distinct topics in clinical allergy and immunology. In this update, we discuss selected recent data that provide clinically and pathogenetically relevant insights or identify potential novel targets and strategies for therapy. The role of the microbiome in shaping allergic immune responses and molecular, as well as cellular mechanisms of disease, is discussed separately and in the context of atopic dermatitis, as an allergic model disease. Besides summarizing novel evidence, this update highlights current areas of uncertainties and debates that, as we hope, shall stimulate scientific discussions and research activities in the field.





Research progress goes ahead fast, and each issue of Allergy distributes a dozen of new and interesting papers providing actual research results, opinions and reviews in different fields of allergy and clinical immunology. Over time, it becomes difficult to keep an overview on the novelties and trends given by these articles. Here, we give an update aiming to summarize interesting papers published in Allergy over the last years and putting them in context with recently published work in the field. As we were not able to cover all fields, we selected three research subjects: (i) Hygiene hypothesis: the role of the microbiome in allergy; (ii) Pathogenic mechanisms of allergic diseases and their potential therapeutic implications; (iii) Atopic dermatitis (AD): skin barrier and allergic inflammation. In our view, the selected papers provide new insights in clinically and pathogenetically important research as well as novel targets and strategies for therapy that might become starting points for future research.





Thursday, September 26, 2013

0 Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology








The Journal of Allergy and Clinical Immunology
Volume 131, Issue 6 , Pages 1479-1490, June 2013



Endotypes and phenotypes of chronic rhinosinusitis: A PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology





Received 31 October 2012; received in revised form 11 February 2013; accepted 14 February 2013. published online 15 April 2013.



Chronic rhinosinusitis (CRS) is a complex disease consisting of several disease variants with different underlying pathophysiologies. Limited knowledge of the mechanisms of these disease subgroups is possibly the greatest obstacle in understanding the causes of CRS and improving treatment. It is generally agreed that there are clinically relevant CRS phenotypes defined by an observable characteristic or trait, such as the presence or absence of nasal polyps. Defining the phenotype of the patient is useful in making therapeutic decisions. However, clinical phenotypes do not provide full insight into all underlying cellular and molecular pathophysiologic mechanisms of CRS. Recognition of the heterogeneity of CRS has promoted the concept that CRS consists of multiple groups of biological subtypes, or “endotypes,” which are defined by distinct pathophysiologic mechanisms that might be identified by corresponding biomarkers. Different CRS endotypes can be characterized by differences in responsiveness to different treatments, including topical intranasal corticosteroids and biological agents, such as anti–IL-5 and anti-IgE mAb, and can be based on different biomarkers that are linked to underlying mechanisms. CRS has been regarded as a single disease entity in clinical and genetic studies in the past, which can explain the failure to identify consistent genetic and environmental correlations. In addition, better identification of endotypes might permit individualization of therapy that can be targeted against the pathophysiologic processes of a patient’s endotype, with potential for more effective treatment and better patient outcomes.



 



 Disclosure of potential conflict of interest: C. A. Akdis receives research support from Novartis, PREDICTA, the Swiss National Science Foundation, MeDALL, the Global Allergy and Asthma European Network, and the Christine Kühne-Center for Allergy Research and Education; has consulted for Actellion, Aventis, Stallergenes, and Allergopharma; is president of the European Academy of Allergy and Clinical Immunology; is a fellow and interest group member of the American Academy of Allergy, Asthma & Immunology (AAAAI); is a former committee member of the Global Allergy and Asthma European Network; and is the director of the Christine Kühne-Center for Allergy Research and Education. C. Bachert has received research support from Novartis and GlaxoSmithKline. M. S. Dykewicz has consultant arrangements with Boehringer Ingelheim, Ista, and Merck. R. M. Naclerio has received travel support from AAAAI; has board memberships with Merck, TEVA, and Sunovion; has received grants from TEVA, Johnson & Johnson, and Kalypsis; and has received payment for lectures from TEVA and Sunovion. R. P. Schleimer has consultant arrangements with Intersect ENT, GlaxoSmithKline, Allakos, and Aurasense; has received research support from the National Institutes of Health; and has received stock/stock options from Allakos. D. Ledford has received travel support from AAAAI; has consultant arrangements with Genentech; and has received payment for lectures from Meda and Genentech. The rest of the authors declare that they have no relevant conflicts of interest.

PII: S0091-6749(13)00367-9

doi:10.1016/j.jaci.2013.02.036





The Journal of Allergy and Clinical Immunology
Volume 131, Issue 6 , Pages 1479-1490, June 2013



Wednesday, September 25, 2013

0 Clinical evaluation of pediatric anaphylaxis and the necessity for multiple doses of epinephrine














Full Text

Original Article  Open Access


















     |   

















Asia Pac Allergy. 2013 Apr;3(2):106-114. English.
Published online 2013 April 26.  http://dx.doi.org/10.5415/apallergy.2013.3.2.106 
Copyright © 2013. Asia Pacific Association of Allergy, Asthma and Clinical Immunology.




































Clinical evaluation of pediatric anaphylaxis and the necessity for multiple doses of epinephrine

Naoyuki Inoue, and Asuka Yamamoto
Department of Pediatrics, Inagi Municipal Hospital, 1171 Omaru, Inagi, Tokyo 206-2801, Japan.

 Correspondence: Naoyuki Inoue. Department of Pediatrics, Inagi Municipal Hospital, 1171 Omaru, Inagi, Tokyo 206-2801, Japan. Tel: +81-42-377-0931, Fax: +81-42-377-1156, Email: nao2014272@yahoo.co.jp 

Received January 08, 2013; Accepted March 25, 2013.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background
Epinephrine administered intramuscularly is the treatment of choice for anaphylaxis, and more than 1 dose is occasionally required.


Objective
To determine clinical background of anaphylaxis for improving the treatment, management, and prognosis of anaphylaxis.


Methods
Children who had satisfied the diagnostic criteria for anaphylaxis according to the National Institute of Allergy and Infectious Disease Food Allergy and Anaphylaxis Network were selected from our hospital from April 1, 2009 to March 31, 2012.


Results
We analyzed 61 patients from the ages of 2 months to 14 years who satisfied the diagnostic criteria for anaphylaxis. Parents of 32 children (52.5%) reported that they had been administered single dose of epinephrine, and 3 children (4.9%) reported receiving multiple doses of epinephrine. The latter group experienced syncope more often (p = 0.049) than the former and suffered more often from comorbid allergic diseases (p = 0.043) that included either bronchial asthma, allergic rhinitis, or atopic dermatitis. Two (3.3%) children experienced biphasic reactions. Patients who experienced a biphasic reaction were more likely to have experienced syncope (p = 0.033), vomiting (p = 0.02), and administration of multiple doses of epinephrine (p = 0.0016).


Conclusion
Our findings lead us to recommend that children receiving more than 1 injection of epinephrine should be observed for 24 hours, because it seems that children with requiring more than 1 injection of epinephrine might be have biphasic reactions.
















Keywords: Epinephrine, Children, Biphasic anaphylaxis, Anaphylaxis.










Tuesday, September 24, 2013

0 Incidence, clinical features and management of acute allergic reactions: the experience of a single, Italian Emergency Department


Eur Rev Med Pharmacol Sci 2013; 17 (1 Suppl): 39-44

Incidence, clinical features and management of acute allergic reactions: the experience of a single, Italian Emergency Department


E.C. Lauritano, A. Novi, M.C. Santoro, I. Casagranda


Emergency Department, SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy. cristianolauritano@yahoo.it







OBJECTIVES: Few data on the incidence, aetiology, clinical features and management of patients with acute allergic reactions presenting to the Emergency Department are currently available. The aim of the study was to report the annual experience of a single Italian adult Emergency Department about anaphylaxis.

PATIENTS AND METHODS: This is a retrospective, case-based study of adult patients attending the Emergency Department in Alessandria, Italy, during the years 2009-2010. We evaluated the medical records of patients satisfying diagnostic codes involving acute allergic reactions. Incidence, demographic data, causative agents, clinical features, management and outcome were reported.

RESULTS: 390 patients with acute allergic reactions were evaluated during the year, corresponding to 0.7% of all Emergency Department visits. Causative agents were recognized in 55.1% of patients and more commonly included drugs (26.9%), insects (14.8%) and foods (8.9%). Cutaneous features were the single most common clinical presentation although two or more clinical features were frequently reported (17.7%). Anaphylaxis was diagnosed in 4.6% of patients. After therapy and a period of monitoring, 92.8% of patients were discharged directly from the Emergency Department, 7.0% were admitted and one patient died, corresponding to a fatality rate of 0.2%.

CONCLUSIONS: Acute allergic reactions are common diseases referring to our Emergency Department. In the half of cases a precipitant agent was identified and cutaneous and/or mucosal changes were often the first feature. Most patients were definitely treated and discharged but about 7.0% of patients required hospitalisation. Observation Unit and Intermediate Care Unit were essential for clinical management of these patients.

Free PDF Download




To cite this article


E.C. Lauritano, A. Novi, M.C. Santoro, I. Casagranda
Incidence, clinical features and management of acute allergic reactions: the experience of a single, Italian Emergency Department

Eur Rev Med Pharmacol Sci 
Year: 2013
Vol. 17 – N. 1 Suppl 
Pages: 39-44



0 Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry

Thorax 67:754-756 doi:10.1136/thoraxjnl-2012-201869


  • Chest clinic



  • Audit update



Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry


This article has been UnlockedFree via Creative Commons: OPEN ACCESS










  1. on behalf of the British Thoracic Society Difficult Asthma Network


+Author Affiliations




  1. 1Centre for Infection and Immunity, Queen’s University of Belfast, Belfast, UK




  2. 2Institute for Lung Health, Department of Infection, Inflammation and Immunity, University of Leicester, Leicester, UK




  3. 3Royal Brompton and Harefield NHS Foundation Trust, London, UK




  4. 4The University of Manchester (MAHSC) and University Hospital of South Manchester, UK




  5. 5Centre for Public Health, Queen’s University of Belfast, Belfast, UK





  1. Correspondence toProfessor Liam G Heaney, Centre for Infection and Immunity, Queen’s University of Belfast, Level 8, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK; l.heaney@qub.ac.uk




  1. Contributors LGH is the coordinator of the British Thoracic Society Difficult Asthma Registry and with JS collated and managed the data for this manuscript. CEB and AM-G and RN co-lead the British Thoracic Society Difficult Asthma Network and all have contributed equally to this manuscript.





  • Received 6 March 2012


  • Accepted 30 March 2012


  • Published Online First 11 May 2012




Abstract


Refractory asthma represents a significant unmet clinical need. Data from a national online registry audited clinical outcome in 349 adults with refractory asthma from four UK specialist centres in the British Thoracic Society Difficult Asthma Network. At follow-up, lung function improved, with a reduction in important healthcare outcomes, specifically hospital admission, unscheduled healthcare visits and rescue courses of oral steroids. The most frequent therapeutic intervention was maintenance oral corticosteroids and most steroid sparing agents (apart from omalizumab) demonstrated minimal steroid sparing benefit. A significant unmet clinical need remains in this group, specifically a requirement for therapies which reduce systemic steroid exposure.

Full Text